Future oncology最新文献_第9页

Precision-medicine management recommendations for advanced non-small cell lung cancer: expert consensus. 晚期非小细胞肺癌的精准医学管理建议：专家共识。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-06-27 DOI: 10.1080/14796694.2025.2518911

Hampig Raphael Kourie, Mounir Ahmed Bachouchi, Malika Makhlouf Gamaz, Emad Anwar Dawoud, Zine-Charaf Mohamed Amir, Hicham Abdelmalek El Attar, Samah Soud Alrehaily, Joseph Fadi Zouein, Nabih Naim, Ameer Dhahir Hameedi, Manwar Abdulelah Alnaqqash, Rami Abdel Rahim Mahfouz, Sarah Masri, Jamil Debs, Taoufiq Barrou, Hatem El Kadi, Vivek Subbiah, Frederique Penault-Llorca

{"title":"Precision-medicine management recommendations for advanced non-small cell lung cancer: expert consensus.","authors":"Hampig Raphael Kourie, Mounir Ahmed Bachouchi, Malika Makhlouf Gamaz, Emad Anwar Dawoud, Zine-Charaf Mohamed Amir, Hicham Abdelmalek El Attar, Samah Soud Alrehaily, Joseph Fadi Zouein, Nabih Naim, Ameer Dhahir Hameedi, Manwar Abdulelah Alnaqqash, Rami Abdel Rahim Mahfouz, Sarah Masri, Jamil Debs, Taoufiq Barrou, Hatem El Kadi, Vivek Subbiah, Frederique Penault-Llorca","doi":"10.1080/14796694.2025.2518911","DOIUrl":"10.1080/14796694.2025.2518911","url":null,"abstract":"Lung cancer is the leading cause of cancer-related death and the second most common cancer worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. In the Middle East and North Africa (MENA) region, lung cancer ranks second in incidence and cancer mortality, with a five-year survival rate of about 8%. To address this pressing health challenge, this expert consensus aims to provide regionally tailored recommendations to improve outcomes for patients with advanced NSCLC in the MENA region. A panel of 15 regional experts convened to develop evidence-informed guidance using a modified Delphi process. Through this structured and collaborative approach, the panel formulated 40 consensus statements covering key areas such as epidemiology, diagnostic workup, molecular testing, and the use of targeted therapies in advanced NSCLC. These statements reflect both global best practices and region-specific considerations, including access to testing and treatment. The resulting recommendations offer the first regionally adapted framework for the management of advanced NSCLC in the MENA region. By unifying clinical practice and promoting precision medicine, these guidelines aim to support clinicians in improving patient care and outcomes across the region.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2321-2327"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pathway to diagnosis of early-onset colorectal cancer: exploring diagnostic intervals and their effect on outcomes. 早发性结直肠癌的诊断途径：探索诊断间隔及其对预后的影响。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-08 DOI: 10.1080/14796694.2025.2526319

Oliver Waddell, Andrew McCombie, Tamara Glyn, John Pearson, Jacqueline Keenan, Frank Frizelle

{"title":"The pathway to diagnosis of early-onset colorectal cancer: exploring diagnostic intervals and their effect on outcomes.","authors":"Oliver Waddell, Andrew McCombie, Tamara Glyn, John Pearson, Jacqueline Keenan, Frank Frizelle","doi":"10.1080/14796694.2025.2526319","DOIUrl":"10.1080/14796694.2025.2526319","url":null,"abstract":"Background: Early-onset colorectal cancer, diagnosed before 50 years (EOCRC), is rising. Previous studies suggest younger patients experience longer diagnostic intervals potentially contributing to poorer outcomes.Research design and methods: A prospective cohort study comparing EOCRC patients in Canterbury, Aotearoa New Zealand, with a control group of late-onset patients (65+ years, LOCRC). Pathways to diagnosis and diagnostic intervals were compared.Results: Sixty-three consecutive EOCRC patients were compared 64 LOCRC patients. The younger cohort was more likely to have advanced disease (stage four in 32% v 17%). Pathways to diagnosis were comparable between the groups (p > 0.05). EOCRC patients, however, visited their GP more frequently before diagnosis (p = 0.04), and 40% had an appraisal interval (time from symptoms to seeking medical advice) exceeding 3 months compared to 26% of LOCRC patients, though this was not significant (p = 0.146). Stage four EOCRCs were less likely to have appraisal intervals >3 months (OR 0.28, p = 0.046).Conclusion: Pathways to diagnosis were similar between EOCRC and LOCRC patients. Shorter diagnostic intervals were associated with advanced disease, indicating that shortening diagnostic intervals alone may not improve outcomes. Diagnosing CRC prior to symptoms develop (screening) is likely the best way to improve outcomes.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2471-2482"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An umbrella review of systematic evidence on the Low Dose Computed Tomography (LDCT) for lung cancer screening. 低剂量计算机断层扫描（LDCT）用于肺癌筛查的系统证据综述。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-15 DOI: 10.1080/14796694.2025.2531428

Stany Mathew, Gowthaman Thangavel, Praveen Pujar, Apourv Pant, Anita Nath

{"title":"An umbrella review of systematic evidence on the Low Dose Computed Tomography (LDCT) for lung cancer screening.","authors":"Stany Mathew, Gowthaman Thangavel, Praveen Pujar, Apourv Pant, Anita Nath","doi":"10.1080/14796694.2025.2531428","DOIUrl":"10.1080/14796694.2025.2531428","url":null,"abstract":"Aim: Despite lung cancer's high mortality rate, many countries still lack organized lung cancer screening programs. This review aims to evaluate the impact of low-dose computed tomography (LDCT) screening on lung cancer diagnosis, mortality, and overall clinical outcomes.Materials and methods: Following the Joanna Briggs Institute methodology for umbrella reviews, a comprehensive search was conducted in PubMed, Embase, and the Cochrane Library for reviews published between January 2013 and December 2023. Eligible meta-analyses included studies comparing LDCT screening with chest X-ray (CXR) or no screening, reporting outcomes such as sensitivity, specificity, and lung cancer mortality. The methodological quality of the included reviews was assessed using AMSTAR-2.Results: Out of 801 citations, 14 meta-analyses met the inclusion criteria. LDCT demonstrated high sensitivity (0.97, 95% CI: 0.94-0.98) and specificity (0.87, 95% CI: 0.82-0.91). It significantly increased early-stage lung cancer detection (RR: 1.31, 95% CI: 1.18-1.45) and reduced lung cancer mortality by 18% (RR: 0.82, 95% CI: 0.75-0.90). However, the reduction in all-cause mortality (RR: 0.91, 95% CI: 0.75-1.06) was not statistically significant. Overdiagnosis and false positives remain essential challenges.Conclusion: This umbrella review confirms that LDCT screening effectively reduces lung cancer mortality, particularly in high-risk populations.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2649-2661"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib. 推进her2阳性转移性乳腺癌的治疗：图卡替尼的作用

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-07 DOI: 10.1080/14796694.2025.2529151

David Fidler, Karen A Gelmon, Christine Simmons

引用次数: 0

Research progress on treatment-associated pneumonitis in lung cancer patients undergoing radiotherapy and immunotherapy. 肺癌放疗和免疫治疗患者治疗相关性肺炎的研究进展。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-08 DOI: 10.1080/14796694.2025.2525067

Caixun Zhang, Youjia Wang, Hanguang Ruan, Vivek Verma, Weimin Xu, Guang Han

引用次数: 0

Immunotherapy and combination treatments for triple-negative breast cancer: a Scopus bibliometric perspective. 免疫疗法和联合治疗三阴性乳腺癌：Scopus文献计量学的观点。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-21 DOI: 10.1080/14796694.2025.2531429

Ninie Nadia Zulkipli, Imilia Ismail, Wan Rohani Wan Taib, Sarina Sulong

{"title":"Immunotherapy and combination treatments for triple-negative breast cancer: a Scopus bibliometric perspective.","authors":"Ninie Nadia Zulkipli, Imilia Ismail, Wan Rohani Wan Taib, Sarina Sulong","doi":"10.1080/14796694.2025.2531429","DOIUrl":"10.1080/14796694.2025.2531429","url":null,"abstract":"Background: Immunotherapy, a cornerstone treatment for triple-negative breast cancer (TNBC), has several limitations as a monotherapy. Global research is actively investigating effective combinatorial immunotherapy treatments for TNBC. Aim: This study aimed to elucidate an overview and research hot spots of immunotherapy and its combinatorial regimens in TNBC management for the past 5 years.Materials & methods: Publications were retrieved from Scopus from 2019 to 2023 and analyzed using Harzing's Publish or Perish, Microsoft Excel, and VOSviewer.Results: The study included a total of 1,818 publications, demonstrating increased publication trends over the years. The most productive continent, country, and journal were Asia (TP = 957), the United States (TP = 653), and Cancers (TP = 123), respectively. The United States and China exhibited the most dynamic inter-country collaboration, evidenced by the highest link strength (69). The United States emerged as the most influential country, recording the highest TLS (520). The analysis of co-occurrence author keywords revealed ICIs, PD-L1, and TME as research hot spots. The thorough integration of knowledge and research on these hot spots may offer an alternative in the management of TNBC.Conclusion: It is imperative to identify combinatorial immunotherapy treatments in order to have better cancer management.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2593-2604"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation. 伴有HRR突变的HER-2阴性乳腺癌新辅助化疗后病理完全缓解。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-20 DOI: 10.1080/14796694.2025.2534767

Xi Chen, Lei Ji, Ying Fan, Qiao Li, Qing Li, Jiayu Wang, Yang Luo, Bo Lan, Shanshan Chen, Ruigang Cai, Fei Ma, Binghe Xu, Pin Zhang

{"title":"Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.","authors":"Xi Chen, Lei Ji, Ying Fan, Qiao Li, Qing Li, Jiayu Wang, Yang Luo, Bo Lan, Shanshan Chen, Ruigang Cai, Fei Ma, Binghe Xu, Pin Zhang","doi":"10.1080/14796694.2025.2534767","DOIUrl":"10.1080/14796694.2025.2534767","url":null,"abstract":"Aims: This study compared pathologic complete response (pCR) rates to neoadjuvant chemotherapy (NAC) in HER2-negative early breast cancer patients with versus without homologous recombination repair (HRR) mutation, focusing on BRCA1/2.Methods: This retrospective cohort study included HER-2-negative breast cancer patients who completed HRR genetic testing and received NAC. The primary endpoint was the pCR rate among HRR mutation carriers and noncarriers.Result: Among 211 HER2-negative breast cancer patients analyzed, 64 (30.3%) harbored pathogenic/likely pathogenic HRR mutations, predominantly in BRCA1 (42.2%), BRCA2 (31.3%), and other HRR genes (26.6%). Hormone receptor positive patients accounted for 55.9% (118/211). Half of the patients (51.2%) treated with platinum-containing regimens. pCR rates were comparable between HRR mutation carriers and noncarriers (26.6% vs. 24.5%, p = 0.750), regardless of hormone receptor status. However, BRCA1 carriers achieved significantly higher pCR rates than BRCA2 carriers (40.7% vs. 10.0%, p = 0.001). Platinum-containing regimens (51.2% of patients) yielded greater benefit in BRCA1 carriers (pCR 61.1% vs. 12.5% in BRCA2; p = 0.022).Conclusion: These data indicated that HRR mutations had no effect on pCR in HER-2 negative patients receiving NAC regardless of hormone receptor status. BRCA1 mutation carriers have a higher rate of pCR and are more benefit from platinum-containing regimen than BRCA2 mutation carriers.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2615-2623"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer. ADJUPANC方案：胰腺癌辅助化疗与放化疗的III期研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-06-29 DOI: 10.1080/14796694.2025.2522061

Xiaofei Zhu, Wenyu Liu, Lingong Jiang, Yangsen Cao, Yusheng Ye, Chunshan Yu, Xiaolan Yin, Huojun Zhang

{"title":"ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer.","authors":"Xiaofei Zhu, Wenyu Liu, Lingong Jiang, Yangsen Cao, Yusheng Ye, Chunshan Yu, Xiaolan Yin, Huojun Zhang","doi":"10.1080/14796694.2025.2522061","DOIUrl":"10.1080/14796694.2025.2522061","url":null,"abstract":"Adjuvant chemotherapy has shown favorable outcomes for pancreatic cancer. However, the role of adding radiotherapy to chemotherapy remained conflicting and lacked robust evidence to show improved survival compared with chemotherapy alone. Previous meta-analyses based on retrospective studies and database demonstrated that patients with lymph nodal metastases, positive microscopic margins or positive margins, or lymphovascular invasion may obtain survival benefits from adjuvant chemoradiotherapy. This multicenter, randomized, open-label, phase III trial aim to compare the efficacy of adjuvant chemoradiotherapy and chemotherapy for pancreatic cancer harboring pathological features predictive of a high risk of recurrence. Seven hundred and seventy patients will be recruited and randomized in a 1:1 ratio into the adjuvant chemoradiotherapy and chemotherapy group. Patients will receive gemcitabine and capecitabine in adjuvant chemotherapy group. In the adjuvant chemoradiotherapy group, patients will first receive the same regimen as that of the adjuvant chemotherapy group and then concurrent chemoradiotherapy (the prescription dose of 50-54 Gy in 25-27 fractions and capecitabine). ADJUPANC aims to investigate whether adjuvant chemoradiotherapy contributes to favorable outcomes for patients with pancreatic cancer harboring lymph nodal metastases, positive microscopic margins or positive margins, or lymphovascular invasion compared with adjuvant chemotherapy. This may provide evidence for individualized treatment for pancreatic cancer.Clinical trial registration: www.clinicaltrials.gov identifier is NCT06427447.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2269-2273"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis. PD-1/PDL-1抑制剂治疗卵巢癌的疗效：系统综述和网络荟萃分析

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-12 DOI: 10.1080/14796694.2025.2530378

Narjisse Ahmadi, Chaimae Kadi, Maryam Benlamari, Zainab Gaouzi, El Mokhtar El Ouali, Amal Bouziane, Redouane Abouqal, Azeddine Ibrahimi

{"title":"Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis.","authors":"Narjisse Ahmadi, Chaimae Kadi, Maryam Benlamari, Zainab Gaouzi, El Mokhtar El Ouali, Amal Bouziane, Redouane Abouqal, Azeddine Ibrahimi","doi":"10.1080/14796694.2025.2530378","DOIUrl":"10.1080/14796694.2025.2530378","url":null,"abstract":"Background: Randomized controlled trials (RCTs) have assessed the efficacy of anti-programmed cell death 1 (PD- 1)/programmed cell death ligand 1 (PD-L1), alone or combined with other therapies, for ovarian cancer. However, the optimal strategy remains unclear. This study evaluated their effectiveness as monotherapy and in combination.Methods: We conducted a systematic review and Frequentist network meta-analysis (NMA) by searching PubMed, ScienceDirect, Web of Science, Scopus, Cochrane Library, and Clinicaltrials.gov databases. This analysis included RCTs comparing PD-L1/PD-1 inhibitors, alone or in combination with other therapies.Results: Six studies involving 3,895 patients and eight treatment combinations were included. PD1/PDL1 inhibitors plus chemotherapy and PD1/PDL1 inhibitors plus ipilimumab showed the greatest progression-free survival (PFS) benefit (hazard ratio (HR) = 0.82, 95% confidence interval [CI]: 0.52-1.07; HR = 0.82, 95% CI:0.51-1.33) and overall survival (OS) (HR = 0.85, 95% CI:0.64-1.14; HR = 0.83, 95% CI:0.45-1.54). These combinations also improved overall response rates (ORR), especially with chemotherapy (OR = 3.06; 95% CI:1.42-6.60). Subgroup analysis suggested that PD-1/PD-L1 inhibitors plus chemotherapy provided the best PFS and OS in PD-L1-positive patients.Conclusion: Combining PD-1/PD-L1 inhibitors with chemotherapy or ipilimumab improved survival in ovarian cancer. However, PD-L1 expression may be a valuable biomarker for predicting the efficacy of PD-1/PD-L1 checkpoint inhibitors.Registration: This systematic review was preregistered in PROSPERO (CRD42022342057). Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42022347967.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2637-2647"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study. 评估土耳其转移性非小细胞肺癌患者一线治疗中不断发展的实践模式的实施情况（ESTIMATE）：一项全国性、多中心、回顾性、真实世界证据研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-24 DOI: 10.1080/14796694.2025.2527477

Mehmet Ali Nahit Sendur, Nuri Karadurmus, Irfan Cicin, Mahmut Gumus, Umut Demirci, Ozgur Ozyilkan, Muhammet Ali Kaplan, Sema Sezgin Goksu, Feyyaz Ozdemir, Cagatay Arslan, Basak Oyan Uluc, Erdem Goker, Muhammed Mustafa Oksuzokyar, Yasemin Esen, Mert Batum, Milan van Rheenan, Bernadette Poellinger

{"title":"Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study.","authors":"Mehmet Ali Nahit Sendur, Nuri Karadurmus, Irfan Cicin, Mahmut Gumus, Umut Demirci, Ozgur Ozyilkan, Muhammet Ali Kaplan, Sema Sezgin Goksu, Feyyaz Ozdemir, Cagatay Arslan, Basak Oyan Uluc, Erdem Goker, Muhammed Mustafa Oksuzokyar, Yasemin Esen, Mert Batum, Milan van Rheenan, Bernadette Poellinger","doi":"10.1080/14796694.2025.2527477","DOIUrl":"10.1080/14796694.2025.2527477","url":null,"abstract":"Background: This national, multicenter, retrospective, non-interventional real-world evidence study aimed to address patient characteristics and systemic treatment practices of metastatic non-small cell lung cancer (mNSCLC) patients in Türkiye.Research design and methods: Over 6 months, 636 adults with mNSCLC at 12 Turkish oncology centers provided retrospective data.Results: Adenocarcinoma was the most common histology, with 95% having distant bone metastases and 64.8% having no comorbidities. The most frequently administered first-line therapy was combination chemotherapy followed by targeted therapy and immunotherapy. Overall, 55.5-69.3% of patients were tested for ALK, EGFR, ROS1, and PD-L1.Conclusions: Biomarker screening in mNSCLC patients in Türkiye was suboptimal compared to other countries, especially in public hospitals.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2525-2535"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0